The Union Health Ministry has proposed changes to the Drugs Rules, 1945, in a move that could ease regulatory requirements for medicinal gases, empty gelatin capsules and disinfectant liquids, according to the latest policy update from New Delhi. The proposal is positioned as a targeted recalibration of drug regulation rather than a wholesale overhaul, but it carries significance for manufacturers, distributors and compliance teams operating in segments that are often treated as peripheral despite their centrality to healthcare delivery.
Regulatory Flexibility
The proposed amendment is intended to provide greater flexibility in the regulatory framework governing these products, which are used across hospitals, pharmaceutical production lines and infection-control systems. Medicinal gases such as oxygen and nitrous oxide are critical to clinical care, while empty gelatin capsules are a basic but indispensable component of oral drug manufacturing. Disinfectant liquids, meanwhile, remain essential to sanitation protocols in both healthcare and industrial settings.
By seeking to relax or rationalise certain provisions, the ministry appears to be responding to practical bottlenecks that can arise when products with distinct risk profiles are governed under the same broad compliance architecture. In regulatory terms, flexibility does not necessarily mean dilution. Rather, it often implies a more proportionate framework in which oversight is aligned with the actual risk, use case and supply-chain characteristics of the product.
Industry Compliance Impact
For industry, the proposal may reduce procedural friction in areas where rigid rules can slow production, certification or distribution without materially improving safety. Manufacturers of medicinal gases and disinfectant liquids often operate under specialised conditions, including storage, transport and handling requirements that differ from those of conventional medicines. Empty gelatin capsule producers likewise function within a highly standardised but volume-sensitive segment of the pharmaceutical supply chain.
A more flexible rulebook could help companies navigate approvals and compliance obligations more efficiently, particularly if the amendments clarify classification, documentation or licensing requirements. That said, any easing of regulation is likely to be closely watched by public health experts and quality-control authorities, especially in a country where medicine safety, contamination risks and supply disruptions remain recurring policy concerns.
The ministry's proposal also reflects a broader administrative trend in India's health governance: the attempt to modernise legacy rules that were drafted in a very different industrial and scientific context. The Drugs Rules, 1945, have been amended repeatedly over the decades, but many of their underlying structures still reflect an older regulatory era. As India's pharmaceutical sector has expanded into a global manufacturing hub, pressure has grown for rules that are more precise, more risk-based and less administratively burdensome.
Policy Modernisation Push
The timing of the proposal is notable because it comes amid sustained attention to regulatory efficiency in sectors tied to public health and manufacturing competitiveness. India's pharmaceutical ecosystem depends not only on finished formulations but also on a wide network of inputs and support materials. When those inputs face avoidable compliance delays, the effects can ripple through production schedules, procurement systems and hospital supply chains.
The ministry's approach suggests an effort to balance two policy goals that are often in tension: ensuring robust public safety oversight while avoiding unnecessary regulatory drag. If implemented carefully, the amendment could improve predictability for industry and help authorities focus inspection and enforcement resources on higher-risk areas.
At the same time, the proposal will likely undergo scrutiny through the standard consultation and notification process before any final legal effect. Stakeholders are expected to examine whether the revised provisions preserve traceability, quality assurance and enforcement powers, particularly for products that have direct implications for patient care and infection prevention.
For now, the amendment proposal stands as a signal that the government is willing to revisit older drug-control provisions in order to better match contemporary manufacturing realities. In a sector where regulatory precision can shape both access and safety, even narrowly framed changes can have outsized operational consequences.

